A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and.

Slides:

Advertisements

Similar presentations

A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and.

Advertisements

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease Shuichiro Takahashi, MD, Daigo Hashimoto,

A Pilot Trial of Unrelated Cord Blood Transplantation (UCBT) and Unmatched Human Placental Derived Stem Cells (HPDSC) in Children and Young Adults with.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

How to Treat MDS without Stem Cell Transplantation

Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.

Biology of Blood and Marrow Transplantation

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation Utilizing CD34 Enrichment and T Cell Addback in Children, Adolescents & Adults with.

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

A Pilot Study of Unrelated Cord Blood (UCB) Transplantation and Unmatched Human Placental Derived Stem Cells (HPDSC) in Pediatric Malignant and Non-Malignant.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation

Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.

Biology of Blood and Marrow Transplantation

Neuroblastoma and Ewing's Sarcoma Associated with ROR1 Expression Can Be Effectively Targeted with NK Cells Modified to Express an Anti ROR1 Chimeric.

Sabina Kersting, Leo F. Verdonck

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Treatment of Severe Mucositis Pain with Oral Ketamine Mouthwash

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

Pauline A. Daniels, DO, Stella M

Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease Nelson J. Chao, MD, MBA, Yevgeniya Gora Foster, MD, Krista Rowe, RN, MSN,

Safety & Efficacy of Liposomal Amphotericin B Followed By Micafungin to Prevent Invasive Fungal Infection in Pediatric Allogeneic Stem Cell Transplantation.

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Biology of Blood and Marrow Transplantation

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Annelies Billen, Jasmin B. L

Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T- Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback.

Potential Use of Human Placenta Derived Stem Cell (HPDSCs) As a Novel Stem Cell Source for the Treatment of Recessive Dystrophic Epidermolysis Bullosa.

ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas Haein Park, Aradhana Awasthi, Janet Ayello,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children.

Neurocognitive & Neurological Outcomes in Children, Adolescents & Young Adults with High-Risk SCD Who Have Undergone Familial Haploidentical (FHI) Allosct.

Rescue of the Mucocutaneous Manifestations in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa (RDEB) By Human Cord Blood Derived Unrestricted.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

A Successful Approach to Decreasing Central Line Associated Blood Stream Infections Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.

Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation.

Outcomes of Second Unrelated Donor Cord Blood Transplants (UCBT) Performed in Children with Graft Failure of Autologous Recovery Following the First UCBT

Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT)

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Pharmacoeconomic Analysis and Clinical Outcomes of Staggered PK-Based Busulfan Dosing during Myeloablative Conditioning for Allogeneic Stem Cell Transplant.

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Does Cryopreserved Hematopoietic Stem Cell Product Need an Expiration Date? Recipients Engrafted Despite Infusion of Products over Five Years in Storage.

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Biology of Blood and Marrow Transplantation

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Similar Survival Between Haploidentical T-Cell Replete Hematopoietic Transplantation (Haplo) with Post-Transplantation Cyclophosphamide (PT-CY) and Unrelated.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

A Low Incidence of Nontuberculous Mycobacterial Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients Elif Unal, Catherine Yen,

Biology of Blood and Marrow Transplantation

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD)

Presentation transcript:

A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949) Michelle Nash, MD, Lauren Harrison, RN, MSN, Michael A. Pulsipher, MD, Qiuhu Shi, PhD, Debra Abrams, MGC, CGC, MLIS, Roger Giller, MD, Berkley Nickerson, RN, MSN, CFNP, Erin Morris, RN, BSN, Olga Militano, PharmD, Janet Ayello, MS, MT(ASCP), Mildred Semidei-Pomales, MS, Sandra Fabricatore, RN, MSN, CPNP, Xiaokui Zhang, PhD, Jodi Gurney, Stacy Herb, Rajarajeswari Sivalenka, PhD, Carmella van de Ven, MS, Nader El-Mallawany, MD, Cori Abikoff, MD, Jessica Hochberg, MD, Lee-Ann Baxter Lowe, PhD, Mitchell S. Cairo, MD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S143-S144 (March 2016) DOI: 10.1016/j.bbmt.2015.11.484 Copyright © 2016 Terms and Conditions

Figure 1 Overall explermental plan MAC: Myeloablative Conditioning: TBI 1200cGy; Ciofarabine 52 mg/m2 ×5 days: Ara-C1 gm/m2/d × 6 days RTC: Reduced Toxicity Conditioning: Busulfan 4 mg/kg/d × 4 days; Fludarabine 30 mg/m2/d × 5 days; Alemtuzumb 2 mg/m2 × 1 days, 6 mg/m2 × 2 days, and 20 mg/m2 × 2 days Biology of Blood and Marrow Transplantation 2016 22, S143-S144DOI: (10.1016/j.bbmt.2015.11.484) Copyright © 2016 Terms and Conditions

Figure 2 Probability of Grade II-IV AGVHD Biology of Blood and Marrow Transplantation 2016 22, S143-S144DOI: (10.1016/j.bbmt.2015.11.484) Copyright © 2016 Terms and Conditions